MBX Biosciences to Participate in Jefferies Healthcare Conference

CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8th, 2023, at 2:30 p.m. Eastern Time and will host 1-on-1 investor meetings.

About MBX Biosciences

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.

Media Inquiries:

Ian StoneEvoke Canale[email protected]619-849-5388

Investor Inquiries:

Irina KofflerLifeSci Advisors[email protected]917-734-7387

You May Also Be Interested In

• NordLocker rebuilds its encrypted cloud storage from the ground up
• Sphere 3D Advances AI Infrastructure Strategy with New Investor Relations and Government Relations Partners
• Simplilearn and UC Santa Barbara Professional and Continuing Education Collaborate to Introduce the Professional Certificate in AI and Machine Learning with a focus on GenAI & Agentic AI